Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 2
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 1…
Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement
Taiho Oncology, Inc.NCT05727176
Phase 1
Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma.
Advanced CholangiocarcinomaFGFR2 Fusion
M.D. Anderson Cancer CenterNCT06439485